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Platelet signaling - blood’s great balancing act
Wolfgang Bergmeier and Lucia Stefanini
Platelets play an essential role in the body’s ability 
to respond to vascular injury (hemostasis). To form a 
hemostatic plug and prevent bleeding from the damaged 
blood vessel, these cells need to be equipped with a 
powerful signaling machinery that allows them to respond 
to trace amounts of agonists produced at injury sites, and 
to rapidly transition from an anti-adhesive/ patrolling 
state to an adhesive state (integrin inside-out activation) 
required for plug formation. However, this highly sensitive 
signaling machinery can also pose a significant risk, as 
premature platelet activation can lead to thrombocytopenia 
(impaired platelet homeostasis) and/or thrombosis. Thus, 
negative feedback within the signaling machinery is 
crucial to balancing sensitivity and speed.
Circulating platelets are also important in various 
aspects of cancer [1]. They support tumor growth by 
providing necessary growth and angiogenic factors. They 
facilitate tumor metastasis by multiple mechanisms, 
including protection of tumor cells from immune 
surveillance while in circulation and adherence to the 
microvasculature at sites of extravasation. To engage 
platelets for these tasks, tumor cells have developed ways 
to activate and aggregate these cells. Consistent with 
these findings, cancer has emerged as a major risk factor 
for thrombotic disease, and a high peripheral platelet 
count correlates with poor survival in various cancers [1]. 
A better understanding of the signaling machinery that 
regulates platelet reactivity is required to determine who 
is at an increased risk for thrombotic disease, both in the 
absence and presence of cancer.
We and others identified the small GTPase RAP1 
as a critical regulator of platelet adhesiveness [2]. RAP1 
serves as a cellular switch that cycles between a GDP-
bound “off-state” and a GTP-bound “on-state”, the latter 
being required for integrin activation. In platelets, RAP1 
activation strongly depends on the guanine nucleotide 
exchange factor, CalDAG-GEFI (RasGRP2). CalDAG-
GEFI activity is regulated by a pair of highly sensitive 
EF hand domains (K
D
~80nM) [3, 4]. These regulatory 
domains provide remarkable sensitivity towards minor 
changes in the cytoplasmic calcium concentration, 
which in resting platelets was measured at ~20-50nM. 
Consistent with this model, platelets lacking functional 
CalDAG-GEFI show markedly impaired sensitivity 
towards threshold concentrations of agonists, both in vitro 
and in vivo. In addition to sensitivity, CalDAG-GEFI is 
also critical for the near-immediate activation of RAP1, 
triggered by rapid calcium mobilization from stores in the 
endoplasmic reticulum. Both RAP1 activation and integrin 
inside-out activation are delayed in platelets from mice 
and humans lacking functional CalDAG-GEFI [3, 5, 6].
As outlined above, a highly sensitive signaling 
machinery needs to be tightly controlled to prevent 
premature platelet activation. In recent work, we identified 
the RAP-GAP, RASA3 (GAP1IP4bp, R-RAS-GAP) as a 
critical negative regulator of RAP1 signaling in platelets 
[7]. RASA3 is perfectly positioned to prevent premature 
integrin activation as it is anchored to the plasma 
membrane of resting platelets by a unique PH/Btk domain. 
Deletion of functional RASA3 in mice led to premature 
activation and clearance of platelets from circulation. 
Concomitant deletion of CalDAG-GEFI reversed this 
phenotype in Rasa3 mutant mice, strongly suggesting that 
RASA3 is critical to restrain the highly sensitive CalDAG-
GEFI/RAP1 signaling pathway. Thus, one can imagine 
RASA3 as a “hand brake”, which is pulled in circulating 
platelets to maintain the cells in a resting state. At sites of 
vascular injury, however, this brake would impair RAP1 
activation and firm platelet adhesion and thus needs 
to be released to allow for hemostatic plug formation. 
Our studies strongly suggest that RASA3 inactivation 
is dependent on signaling by phosphoinositide 3 kinase 
(PI3K), downstream of the platelet receptor for ADP, 
P2Y12. More specifically, we observed that Rasa3 mutant 
platelets did not require feedback signaling via ADP and 
P2Y12, and that RAP1-dependent integrin activation in 
these cells was insensitive to inhibitors of P2Y12 or PI3K. 
Consistent with this data, platelet adhesion at sites of 
injury in Rasa3 mutant mice was insensitive to inhibitors 
of P2Y12. 
Together, these studies suggest that the antagonistic 
balance between CalDAG-GEFI and RASA3 signaling 
is critical for the fine-tuning of platelet adhesiveness, 
both in the circulation and at sites of vascular injury. 
Editorial
Figure 1: The antagonistic balance between the RAP 
GTPase regulators, CalDAG-GEFI and RASA3, 
controls platelet adhesiveness both in circulation and 
at sites of vascular injury. 
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Genetic and environmental factors that shift the balance 
towards RAP1 activation may lead to thrombocytopenia 
and thrombosis, while those that lead to impaired RAP1 
activation may cause bleeding in patients (Figure 1). 
Future efforts should be directed towards the testing of 
this hypothesis in humans, studies that will greatly benefit 
from the development of novel assays that monitor the 
expression and activity of CalDAG-GEFI, RASA3, and 
RAP1. The long-term benefit of this work could be a more 
personalized approach to thrombosis prevention, which is 
based on inter-individual differences in the regulation of 
this important platelet signaling pathway. 
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